Ibutamoren (MK-677):
Oral GH Secretagogue

Compound class

Non-peptide ghrelin receptor agonist / GHSR agonist

Also known as

MK-677, Ibutamoren mesylate, Nutrobal

Delivery format

Oral capsule, once daily

Primary mechanism

Ghrelin receptor agonism → pulsatile GH release → IGF-1 elevation

Secondary effects

Slow-wave sleep extension, appetite stimulation, potential initial water retention

Half-life

Approximately 24 hours; supports once-daily dosing

Key distinction

The only oral GH secretagogue in the VitalRx catalog

Ghrelin Receptor Agonism: The GH Pulse Trigger

Ghrelin is the endogenous ligand for the growth hormone secretagogue receptor (GHSR-1a), expressed primarily in the pituitary and hypothalamus. When ghrelin binds GHSR-1a in the pituitary, it triggers growth hormone release in pulses, the same pulsatile pattern that characterizes natural GH secretion. Ibutamoren mimics this signal, binding selectively to GHSR-1a and stimulating pituitary GH secretion without interfering with the feedback mechanisms that regulate GH output. The result is elevated GH pulsatility and elevated circulating IGF-1, the primary downstream mediator of GH's anabolic, reparative, and metabolic effects.

IGF-1 Elevation

Growth hormone stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the downstream anabolic signal responsible for most of GH's tissue-level effects: muscle protein synthesis, collagen production, bone density maintenance, fat metabolism, and cellular repair. Ibutamoren consistently elevates IGF-1 in clinical studies. The elevation is sustained with daily dosing and is one of the more reliable biomarker signals available for monitoring protocol efficacy.

Slow-Wave Sleep Extension

Ghrelin receptor activation has established effects on sleep architecture, specifically promoting slow-wave (N3) sleep duration. Ibutamoren extends the time spent in deep slow-wave sleep, which is both the stage during which endogenous GH pulsatility is highest and the stage most responsible for physical recovery, immune consolidation, and memory consolidation. This sleep effect is clinically significant in its own right. Patients who take Ibutamoren in the evening often notice an improvement in sleep depth and morning recovery before they notice compositional changes.

Oral Bioavailability: Why This Matters Clinically

The peptide bonds in injectable secretagogues like Ipamorelin and Sermorelin are degraded by gastrointestinal enzymes, which is why they cannot be taken orally and must be injected subcutaneously. Ibutamoren is a non-peptide small molecule with high oral bioavailability and a 24-hour half-life. This is not a minor administrative convenience. It meaningfully changes the compliance profile, the barrier to starting a GH secretagogue protocol, and the suitability of this approach for patients who cannot or will not self-inject.

Appetite Stimulation: The Expected Ghrelin Effect

Ghrelin is also known as the hunger hormone. Its endogenous function includes appetite stimulation alongside GH regulation. Because Ibutamoren agonizes the same receptor, appetite increase is a common and expected side effect, particularly early in a protocol. For patients in muscle-building phases this is often a useful effect. For those using Ibutamoren for sleep, longevity, or recovery where caloric surplus is not the goal, managing appetite through meal timing and dietary structure is important. This effect typically attenuates within 2 to 4 weeks.

Patients who want the documented benefits of GH axis stimulation (improved body composition, enhanced recovery, better sleep, metabolic optimization) but prefer or require an oral protocol now have a clinically legitimate path. IGF-1 levels are a reliable and trackable biomarker for monitoring protocol efficacy.

Elevated GH and IGF-1 support muscle protein synthesis and reduce lean mass catabolism, the muscle-wasting associated with caloric restriction, aging, or recovery from illness or injury. For body recomposition phases, Ibutamoren's anabolic signaling supports preservation of lean mass while fat oxidation proceeds.

The slow-wave sleep extension associated with Ibutamoren's ghrelin receptor agonism is one of its most consistently reported and earliest-onset effects. Patients on evening dosing protocols typically notice deeper, more restorative sleep within the first week, before compositional or performance changes are apparent.

GH and IGF-1 promote lipolysis, the mobilization and oxidation of stored fat, and have opposing effects to insulin on adipose tissue accumulation. Visceral fat reduction is documented with GH secretagogue protocols over sustained use. The effect accumulates over months rather than weeks.

IGF-1 is a key regulator of osteoblast activity and bone remodeling. GH secretagogue protocols including Ibutamoren are associated with improvements in bone mineral density over extended use, relevant for patients with age-related bone density decline.

A single evening capsule replaces the daily subcutaneous injection required by all other GH secretagogues in this catalog. For patients managing multiple protocols or those with injection fatigue, consolidating GH secretagogue dosing into an oral capsule meaningfully reduces protocol burden.

The Injection-Averse Patient

Patients who want a GH secretagogue protocol but are unwilling or unable to self-administer daily subcutaneous injections. Needle phobia, injection site complications, travel schedules, or a strong preference for oral medication are all legitimate reasons. Ibutamoren delivers comparable GH axis benefits without the injection requirement.

Patients Focused on Sleep Quality and Recovery

The ghrelin receptor agonism that drives GH release also directly extends slow-wave sleep. Patients whose primary motivation is improved sleep quality and overnight recovery (athletes in heavy training, high-output professionals, aging patients experiencing sleep degradation) will notice the sleep benefits early in the protocol.

Muscle Preservation During Caloric Restriction

Elevated GH and IGF-1 support lean mass retention during phases of caloric deficit. Patients pursuing fat loss who want to protect muscle mass are a natural fit, and the initial appetite stimulation typically attenuates meaningfully over the first few weeks.

Patients Managing Multiple Injectable Protocols

Patients already injecting BPC-157, Thymosin Alpha-1, or other compounds daily may prefer to keep their GH secretagogue in oral format to reduce total injection burden. Ibutamoren's oral delivery integrates cleanly into complex multi-compound protocols.

Older Patients with Age-Related GH Decline

GH pulsatility and IGF-1 decline progressively with age, contributing to muscle wasting, fat accumulation, bone loss, and reduced sleep quality. For older patients who want to address GH axis decline but prefer once-daily oral dosing, Ibutamoren offers a low-friction entry point into GH secretagogue therapy.

Available Doses

12.5mg and 25mg capsules, 30-count bottles. 12.5mg is the standard starting dose. It provides meaningful GH axis stimulation while allowing individual assessment of the ghrelin mechanism effects (appetite, water retention). 25mg is appropriate for patients who have tolerated 12.5mg well and want greater GH pulse amplitude.

Timing: Evening Dosing Is Standard

Ibutamoren is almost universally dosed in the evening, 30 to 60 minutes before bed. The rationale is twofold: it amplifies the natural GH pulse that occurs during the first hours of slow-wave sleep, and the appetite stimulation is less disruptive when it occurs during sleeping hours. Evening dosing also allows any mild initial water retention to resolve overnight.

Cycle Structure

Ibutamoren can be used in continuous daily protocols or defined cycles. Common approaches include continuous use for 3 to 6 months followed by a structured break, or cycling of 8 weeks on / 4 weeks off. Because IGF-1 remains elevated with sustained daily use, longer-term monitoring of IGF-1 and fasting glucose is standard practice.

Appetite and Water Retention Management

Appetite increase is expected early in the protocol due to the ghrelin mechanism and typically attenuates within 2 to 4 weeks. Mild initial water retention, typically 1 to 2kg, may occur as IGF-1 rises. This is transient and resolves with protocol continuation. Both are expected early responses, not adverse effects requiring discontinuation.

Stacking Considerations

Ibutamoren stacks naturally with CJC-1295/Ipamorelin for dual-pathway GH stimulation. DSIP or Epithalon are logical additions for patients whose sleep quality is also a protocol goal. For body composition patients, BPC-157 or the Wolverine Stack can be added for tissue repair and recovery. Your provider will advise on appropriate combinations.

Ibutamoren 12.5mg Capsules, 30 Count

Standard starting dose. Once-daily evening administration. GH axis stimulation, IGF-1 elevation, and slow-wave sleep extension without subcutaneous injection.

$118.30

Oral Capsule

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping

Ibutamoren 25mg Capsules, 30 Count

Full-dose format for patients titrating up from 12.5mg. Greater GH pulse amplitude and IGF-1 elevation. Once-daily evening administration.

$221.90

Oral Capsule

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping